Working clinical interpretation

• Primary severe TR can cause marked RA enlargement and right-heart failure.
• Doppler-estimated pulmonary artery pressure can be unreliable when TR is very severe. Therefore, "moderate PAH" on echo must be confirmed and characterized with right-heart catheterization (RHC) if it will change treatment.

Cause evaluation

1. Confirm severity and mechanism on expert echocardiography

• TR mechanism: functional/secondary versus primary leaflet pathology
• Tricuspid annular diameter, leaflet tethering/coaptation gap
• RV size and systolic function: TAPSE, S', FAC, RV strain
• RA size, IVC diameter and collapsibility, estimated RA pressure
• LV ejection fraction and diastolic function
• Mitral valve morphology and stenosis/regurgitation, especially rheumatic MS
• Aortic valve disease
• Interatrial shunt: ASD, sinus venosus ASD, partial anomalous pulmonary venous return
• Ebstein anomaly
• Pericardial effusion/constriction
• Echo signs of acute RV pressure overload or thrombus-in-transit

2. Immediately exclude acute pulmonary embolism and other acute causes

• ECG, chest radiograph, serial troponin, BNP/NT-proBNP
• ABG/VBG, pulse oximetry, lactate
• CBC, renal function, electrolytes, liver panel, coagulation profile
• Pregnancy test before radiation/contrast studies where relevant
• D-dimer only if low/intermediate pretest probability
• CT pulmonary angiography if PE is likely and no contraindication
• Lower-limb venous Doppler ultrasound
• V/Q scan if CTPA is contraindicated, or if chronic thromboembolic pulmonary hypertension (CTEPH) is suspected
• Evaluate for acute coronary syndrome and acute pericardial disease as indicated

3. Define the pulmonary-hypertension group

• Mean PA pressure
• Pulmonary artery wedge pressure (PAWP)
• Cardiac output/index
• Pulmonary vascular resistance (PVR)
• RA pressure and mixed venous oxygen saturation

• PFT with DLCO, ABG, high-resolution CT chest as needed
• Sleep study/overnight oximetry
• V/Q scan to exclude CTEPH, even if a prior CT is nondiagnostic
• ANA, ENA, anti-centromere, anti-Scl-70 and other connective-tissue testing guided by history
• HIV test, hepatitis/liver tests and abdominal ultrasound for portal hypertension
• Thyroid function
• Review medications, anorexigens, stimulants/recreational drugs
• Family history of PAH, venous thromboembolism, congenital heart disease
• If indicated: thrombophilia/antiphospholipid testing, especially with unprovoked VTE or recurrent miscarriage

4. Identify the specific TR cause

• PH with RV pressure overload
• RV failure/cardiomyopathy
• Left-sided valve disease, especially rheumatic mitral disease
• Acute or chronic PE/CTEPH
• ASD or other left-to-right shunt
• Atrial fibrillation causing RA/annular enlargement, called atrial functional TR

• Rheumatic heart disease, often with concomitant mitral disease
• Infective endocarditis, particularly fever, bacteremia, IV drug use, indwelling catheter
• Pacemaker/ICD lead-related TR
• Ebstein anomaly or other congenital disease
• Carcinoid heart disease: flushing, diarrhea, liver metastases
• Trauma, prior biopsy, radiation
• Connective-tissue disease or drug-related valvulopathy

Management

A. Acute stabilization

1. Monitoring
   • Oxygen saturation, BP, ECG telemetry, urine output
   • Serial lactate, renal function, electrolytes, liver tests
   • Early cardiology and PH-team involvement
2. Oxygen
   • Give oxygen for hypoxemia and treat the precipitating respiratory cause.
   • Avoid unnecessary hyperoxia in a stable, normoxemic patient.
3. Relieve systemic congestion
   • IV loop diuretic, for example furosemide, titrated to clinical response.
   • Monitor potassium, magnesium, creatinine, BP, and urine output.
   • Sodium restriction and individualized fluid restriction.
   • Add a thiazide-type diuretic or mineralocorticoid receptor antagonist only when clinically appropriate and monitored.
4. Avoid harmful volume strategy
   • Do not give routine large fluid boluses in a congested patient with severe TR/RV failure.
   • A small, carefully reassessed fluid challenge is only appropriate if true underfilling is suspected.
   • Hypotension/shock requires ICU-based RV-failure management, often with vasopressor support and expert guidance.
5. Treat the acute trigger
   • If acute PE is confirmed or strongly suspected and bleeding risk is acceptable: therapeutic anticoagulation.
   • If high-risk PE with shock: urgent PE response-team/cardiology consultation for reperfusion strategy, such as systemic thrombolysis, catheter therapy, or surgical embolectomy as appropriate.
   • Treat arrhythmia, infection, acute ischemia, anemia, thyroid disorder, or uncontrolled lung disease.

B. Cause-directed long-term treatment

• PH due to mitral/left-heart disease: optimize the left-sided disease. Rheumatic mitral stenosis may require balloon mitral valvotomy or surgery, depending on anatomy.
• CTEPH: lifelong anticoagulation plus referral to a CTEPH center for operability assessment for pulmonary endarterectomy. Balloon pulmonary angioplasty or targeted therapy may be used in selected inoperable/residual cases.
• Group 3 PH: oxygen for chronic hypoxemia, smoking cessation, optimize COPD/ILD care, and treat sleep apnea/obesity-hypoventilation.
• Group 1 PAH: only after RHC confirms precapillary PAH and after PH-center assessment. Treatment may include an endothelin-receptor antagonist plus a PDE-5 inhibitor in suitable patients, with escalation based on risk. Do not start PAH-specific drugs empirically merely from an echo-estimated PA pressure.
• AF: rate/rhythm strategy and anticoagulation according to thromboembolic risk and valve context. Restoration of sinus rhythm may help atrial functional TR in selected patients.
• Endocarditis: prolonged culture-directed IV antibiotics and early surgical discussion if severe valve destruction, persistent infection, recurrent emboli, or refractory heart failure.

C. Management of severe TR

• Severe symptomatic primary TR with congestion, before irreversible severe RV dysfunction or hepatic/renal injury
• Severe TR at the time of left-sided valve surgery
• Significant symptomatic secondary TR despite optimized treatment of the cause, after assessment of RV function, pulmonary vascular disease, anatomy, and surgical risk

Practical priority order for this patient

1. Stabilize and assess for high-risk PE/RV failure today.
2. Confirm whether chest pain/dyspnea are due to acute PE, ACS, infection, or arrhythmia.
3. Repeat expert echo with detailed RV, TR, mitral-valve, and shunt assessment.
4. V/Q scan and CTPA strategy for thromboembolic disease.
5. RHC after initial stabilization to classify PH.
6. Treat congestion with monitored diuresis and correct the underlying PH/valve/lung/thromboembolic cause.
7. Early PH and valve-team referral for definitive TR planning.